The DCTN1 (Dynactin 1) antibody targets the protein encoded by the DCTN1 gene, a critical component of the dynactin complex. Dynactin, a multi-subunit complex, interacts with cytoplasmic dynein to facilitate retrograde microtubule-based transport of organelles, vesicles, and other cargoes within cells. DCTN1. also known as p150^Glued, serves as the largest subunit of dynactin, anchoring the complex to microtubules via its N-terminal CAP-Gly domain and regulating dynein-mediated motility. Dysfunction in DCTN1 is linked to neurodegenerative disorders, particularly Perry syndrome and amyotrophic lateral sclerosis (ALS), where mutations disrupt axonal transport, leading to neuronal degeneration. Research using DCTN1 antibodies focuses on understanding its role in cellular trafficking, mitosis, and disease mechanisms. These antibodies are widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions in both normal and pathological contexts. Studying DCTN1 also provides insights into therapeutic strategies targeting dynein-dynactin dysfunction in neurodegeneration and cancer.